Demonstration of Cross-Protective Vaccine Immunity against an Emerging Pathogenic Ebolavirus Species

English version České info

A major challenge in developing vaccines for emerging pathogens is their continued evolution and ability to escape human immunity. Therefore, an important goal of vaccine research is to advance vaccine candidates with sufficient breadth to respond to new outbreaks of previously undetected viruses. Ebolavirus (EBOV) vaccines have demonstrated protection against EBOV infection in nonhuman primates (NHP) and show promise in human clinical trials but immune protection occurs only with vaccines whose antigens are matched to the infectious challenge species. A 2007 hemorrhagic fever outbreak in Uganda demonstrated the existence of a new EBOV species, Bundibugyo (BEBOV), that differed from viruses covered by current vaccine candidates by up to 43% in genome sequence. To address the question of whether cross-protective immunity can be generated against this novel species, cynomolgus macaques were immunized with DNA/rAd5 vaccines expressing ZEBOV and SEBOV glycoprotein (GP) prior to lethal challenge with BEBOV. Vaccinated subjects developed robust, antigen-specific humoral and cellular immune responses against the GP from ZEBOV as well as cellular immunity against BEBOV GP, and immunized macaques were uniformly protected against lethal challenge with BEBOV. This report provides the first demonstration of vaccine-induced protective immunity against challenge with a heterologous EBOV species, and shows that Ebola vaccines capable of eliciting potent cellular immunity may provide the best strategy for eliciting cross-protection against newly emerging heterologous EBOV species.

Vyšlo v časopise: Demonstration of Cross-Protective Vaccine Immunity against an Emerging Pathogenic Ebolavirus Species. PLoS Pathog 6(5): e32767. doi:10.1371/journal.ppat.1000904
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1000904

Souhrn

Zdroje

1. FauquetCM

MayoMA

ManiloffJ

DesselbergerU

BallLA

2005 Virus Taxonomy: VIIIth Report of the International Committee on Taxonomy of Viruses. New York Academic Press

2. GrosethA

FeldmannH

StrongJE

2007 The ecology of Ebola virus. Trends Microbiol 15 408 416

3. TownerJS

SealyTK

KsiazekTG

NicholST

2007 High-throughput molecular detection of hemorrhagic fever virus threats with applications for outbreak settings. J Infect Dis 196 Suppl 2 S205 212

4. SullivanNJ

GeisbertTW

GeisbertJB

ShedlockDJ

XuL

2006 Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med 3 e177

5. SullivanNJ

GeisbertTW

GeisbertJB

XuL

YangZY

2003 Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 424 681 684

6. SullivanNJ

SanchezA

RollinPE

YangZY

NabelGJ

2000 Development of a preventive vaccine for Ebola virus infection in primates. Nature 408 605 609

7. MartinJE

SullivanNJ

EnamaME

GordonIJ

RoedererM

2006 A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vaccine Immunol 13 1267 1277

8. JonesSM

FeldmannH

StroherU

GeisbertJB

FernandoL

2005 Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med 11 786 790

9. BukreyevA

RollinPE

TateMK

YangL

ZakiSR

2007 Successful topical respiratory tract immunization of primates against Ebola virus. J Virol 81 6379 6388

10. WarfieldKL

SwensonDL

OlingerGG

KalinaWV

AmanMJ

2007 Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J Infect Dis 196 Suppl 2 S430 437

11. TownerJS

SealyTK

KhristovaML

AlbarinoCG

ConlanS

2008 Newly discovered ebola virus associated with hemorrhagic fever outbreak in Uganda. PLoS Pathog 4 e1000212

12. SantraS

SeamanMS

XuL

BarouchDH

LordCI

2005 Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates. J Virol 79 6516 6522

13. LeeJE

FuscoML

HessellAJ

OswaldWB

BurtonDR

2008 Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature 454 177 182

14. ReedDS

MohamadzadehM

2007 Status and challenges of filovirus vaccines. Vaccine 25 1923 1934

15. OswaldWB

GeisbertTW

DavisKJ

GeisbertJB

SullivanNJ

2007 Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLoS Pathog 3 e9

16. SullivanNJ

MartinJE

GrahamBS

NabelGJ

2009 Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule. Nat Rev Microbiol 7 393 400

17. BettsMR

CasazzaJP

KoupRA

2001 Monitoring HIV-specific CD8+ T cell responses by intracellular cytokine production. Immunol Lett 79 117 125

18. SantraS

SunY

Korioth-SchmitzB

FitzgeraldJ

CharbonneauC

2009 Heterologous prime/boost immunizations of rhesus monkeys using chimpanzee adenovirus vectors. Vaccine 27 5837 5845

19. SantraS

KorberBT

MuldoonM

BarouchDH

NabelGJ

2008 A centralized gene-based HIV-1 vaccine elicits broad cross-clade cellular immune responses in rhesus monkeys. Proc Natl Acad Sci U S A 105 10489 10494

20. AciernoPM

SchmitzJE

GorgoneDA

SunY

SantraS

2006 Preservation of functional virus-specific memory CD8+ T lymphocytes in vaccinated, simian human immunodeficiency virus-infected rhesus monkeys. J Immunol 176 5338 5345

21. SeamanMS

SantraS

NewbergMH

PhilipponV

MansonK

2005 Vaccine-elicited memory cytotoxic T lymphocytes contribute to Mamu-A*01-associated control of simian/human immunodeficiency virus 89.6P replication in rhesus monkeys. J Virol 79 4580 4588

22. Fisher-HochSP

PlattGS

LloydG

SimpsonDI

NeildGH

1983 Haematological and biochemical monitoring of Ebola infection in rhesus monkeys: implications for patient management. Lancet 2 1055 1058

23. GeisbertTW

HensleyLE

LarsenT

YoungHA

ReedDS

2003 Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. Am J Pathol 163 2347 2370

24. FeldmannH

NicholST

KlenkHD

PetersCJ

SanchezA

1994 Characterization of filoviruses based on differences in structure and antigenicity of the virion glycoprotein. Virology 199 469 473

25. GeisbertTW

JahrlingPB

2003 Towards a vaccine against Ebola virus. Expert Rev Vaccines 2 777 789

26. YuJS

LiaoHX

GerdonAE

HuffmanB

ScearceRM

2006 Detection of Ebola virus envelope using monoclonal and polyclonal antibodies in ELISA, surface plasmon resonance and a quartz crystal microbalance immunosensor. J Virol Methods 137 219 228

27. LetvinNL

MontefioriDC

YasutomiY

PerryHC

DaviesME

1997 Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination. Proc Natl Acad Sci U S A 94 9378 9383

28. SunY

SantraS

SchmitzJE

RoedererM

LetvinNL

2008 Magnitude and quality of vaccine-elicited T-cell responses in the control of immunodeficiency virus replication in rhesus monkeys. J Virol 82 8812 8819

29. AokiK

BarkerC

DanthinneX

ImperialeMJ

NabelGJ

1999 Efficient generation of recombinant adenoviral vectors by Cre-lox recombination in vitro. Mol Med 5 224 231

30. PerfettoSP

ChattopadhyayPK

LamoreauxL

NguyenR

AmbrozakD

2006 Amine reactive dyes: an effective tool to discriminate live and dead cells in polychromatic flow cytometry. J Immunol Methods 313 199 208